INO-1001

Cat. No. M1785

Synonym:

3-Aminobenzamide

Size	Price	Availability
Free Sample (0.5-1 mg)	USD 0	In stock
10mM*1mL in Water	USD 50 USD50	In stock
200mg	USD 50 USD50	In stock
500mg	USD 90 USD90	In stock
1g	USD 140 USD140	In stock

Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation

Purity: 99.89%
COA
MSDS
H-NMR
LC/MS

Product Information

Biological Activity

INO-1001 is a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. The present study tested INO-1001 for its in vivo effect on the chemoresponse of two p53 deficient tumors, human breast cancer MDA-MB-231 and murine mammary carcinoma MCa-K. Doxorubicin was used as the DNA damaging agent and tumor growth delay assay was used as the endpoint. Results showed that INO-1001 was highly effective in enhancing the anti-tumor effects of Doxorubicin for both MDA-MB-231 (EF=1.88) and MCa-K (EF=1.64).

Product Citations

Bioact Mater. 2022 Feb 9.

pH and lipase-responsive nanocarrier-mediated dual drug delivery system to treat periodontitis in diabetic rats
INO-1001 purchased from AbMole
Cell Commun Signal. 2020 Feb 17;18(1):27.

mTOR May Interact With PARP-1 to Regulate Visible Light-Induced Parthanatos in Photoreceptors
INO-1001 purchased from AbMole

Customer Product Validations & Biological Datas

	Source	Exp Gerontol (2007). Figure 2. INO-1001
	Method	i.p.
	Cell Lines	male Lewis rats
	Concentrations	5 mg/kg
	Incubation Time	2 h
	Results	Single dose treatment with the potent PARP-inhibitor INO-1001 notably decreased PAR formation both in the myocardium and the aortic wall.

Protocol (for reference only)

Cell Experiment
Cell lines	cultured podocytes
Preparation method	Apoptosis detection. Apoptotic nuclei of cultured podocytes were detected on paraformaldehyde-fixed cells using DAPI (4′,6-diamidino-2-phenylindole) staining (1 μg/ml) for 10 min. Cells were analyzed under a fluorescence microscope and assessed for chromatin condensation and segregation. Caspase-3 activity was measured in podocyte extracts using EnzCheck Caspase-3 Assay kit (Molecular Probes) following the manufacturer’s protocol. Nuclear extracts were prepared using Transfactor DB Nuclear extraction kit (Clontech BD Bioscience) following the manufacturer’s protocol. Western blotting was performed using NFκB p50 (Santa Cruz Biotechnology) antibody. NFκB p50 nuclear binding assay was performed using TransFactor Colorimetric kit (Clontech BD) according to the manufacturer’s protocol.
Concentrations	200 nmol/l
Incubation time	45 min

Animal Experiment
Animal models	diabetic nephropathy of Leprdb/db mice model
Formulation	sterile water
Dosages	60 mg/kg initiated at 5 weeks of age to around 8 weeks of age
Administration	oral in drinking water

Chemical Information

Molecular Weight	136.15
Formula	C7H8N2O
CAS Number	3544-24-9
Solubility (25°C)	DMSO 22 mg/mL Water ≥ 4 mg/mL
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Conversion of different model animals based on BSA (PMID: 27057123)

Species	Mouse	Rat	Rabbit	Guinea pig	Hamster	Dog
Weight (kg)	0.02	0.15	1.8	0.4	0.08	10
Body Surface Area (m²)	0.007	0.025	0.15	0.05	0.02	0.5
K_m factor	3	6	12	8	5	20

Animal A (mg/kg) = Animal B (mg/kg) multiplied by	Animal B K_m
	Animal A K_m

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the K_m factor for a mouse and then divide by the K_m factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Roesner JP, et al. Shock. Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size.

[2] Bedikian AY, et al. Cancer Invest. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

[3] Morrow DA, et al. J Thromb Thrombolysis. A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial.

[4] Robert S B Clark, et al. J Neurotrauma. Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice

[5] Mason KA, et al. Invest New Drugs. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.

[6] Radovits T, et al. Exp Gerontol. Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction.

[7] Csaba Szabo, et al. Diabetes. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice

Related PARP Products
DSB-1522 DSB-1522 is a PARP1 inhibitor that can be used in tumor-related studies.
DM-5167 DM-5167 is a PARP1 inhibitor that can be used in studies related to triple negative breast cancer.
NMS-03305293 NMS-03305293 is a PARP inhibitor with high selectivity for PARP1 isoforms and low DNA capture effect, which specifically kills BRCA mutated tumor cells. In addition, NMS-03305293 can penetrate the blood-brain barrier and can be used in studies related to CNS tumors and brain metastatic tumors.
SNV1521 SNV1521 is a potential best-in-class (BIC), highly selective and CNS-permeable PARP1 inhibitor.
Basroparib Basroparib is an orally active selective inhibitor of end-anchor polymerase (TNKS) and an inhibitor of ribose polymerase (PARP) with antitumor activity.

Catalog

By Signaling Pathways

By Product Type

Signaling Pathways